What’s new in 2026?
Two November publications address different points in the preventive treatment pathway. The Taiwan Headache Society’s update to its 2022 consensus places therapies that target calcitonin gene-related peptide (CGRP) among the first-line options for episodic and chronic migraine. The Spanish Headache Study Group (GECSEN) Delphi consensus defines control in terms of the headache burden that remains and sets out decisions on continuing, switching, combining and withdrawing treatment.
GECSEN reached agreement on 14 statements in two rounds, with 88 specialists participating in round one and 48 in round two. These statements are expert consensus informed by a literature review. The Taiwan recommendations in this summary are drawn from the published abstract and publisher summary.
1. Identify who should be offered prevention
Start with a history of monthly headache and migraine days, attack severity, functional impact, and how reliably acute treatment works. Record disability between attacks as well as on headache days. Discuss the patient’s priorities before choosing a preventive.
| Source | When to consider preventive treatment |
|---|---|
| Taiwan Headache Society | Four or more headache days per month. Other reasons include substantial disability, failure of or contraindications to acute treatment, complicated migraine with severe aura, or a preference for prevention after discussing benefits and risks. |
| Spanish GECSEN consensus | Four or more migraine days or moderate to severe headache days per month, with particular weight given to impaired quality of life. |
The two thresholds count different types of days. A history of frequent mild headaches is therefore interpreted differently under the two formulations. Record the type of day consistently so the baseline can be compared with follow-up.
2. Choose an initial preventive
The Taiwan guideline includes a CGRP-targeted option at the first treatment decision for both episodic and chronic migraine. It does not require failure of multiple preventive drugs before initiation. Drug selection still depends on the individual patient and the setting.
| CGRP-targeted class | Preventive agents listed by the Taiwan guideline |
|---|---|
| Monoclonal antibodies directed at the CGRP pathway | Erenumab, fremanezumab, galcanezumab and eptinezumab |
| Small-molecule CGRP receptor antagonists, or gepants | Rimegepant and atogepant |
GECSEN recommends considering prior and current treatments, comorbidities, expected benefit and tolerability, patient preferences, and plans for pregnancy. Where several choices are clinically appropriate, discuss how the method of administration and access will affect the patient’s ability to continue treatment. The first-line recommendation describes clinical positioning in the Taiwan guideline. Local prescribing and reimbursement criteria may differ.
3. Set a three-month target and measure what remains
Agree on a target before starting. GECSEN’s ideal is freedom from attacks, with improved quality of life as a central goal. When freedom from attacks is unattainable, look at the number and intensity of remaining attacks and the benefit the patient experiences.
| GECSEN target | Migraine or moderate to severe headache days per month at three months |
|---|---|
| Ideal | Freedom from attacks |
| Optimal control | Fewer than four days |
| Moderate control | Four to six days |
A patient can improve substantially from baseline and still have enough residual burden to need treatment adjustment. Another patient may report a meaningful gain in function that a day count alone misses. Review headache intensity, function, and quality of life alongside frequency. GECSEN suggests using the Patient Global Impression of Change when helpful, with a score of 1 corresponding to its optimal target and 3 to its moderate target.
4. Continue, switch or add treatment
At the three-month review → compare residual burden with the agreed target → review treatment and tolerability → decide together whether to maintain, switch or add therapy.
1. Optimal control. Continue effective therapy and agree when to revisit the decision. GECSEN generally recommends maintaining preventive treatment for at least 12 months after optimal control has been achieved. 2. Target still unmet after six months. GECSEN supports considering a switch when the recommended dose and regimen have been used. Check for comorbidities or other factors that might have interfered with response. The panel discusses switching within a class or to a different preventive. It notes that data on switching between monoclonal antibodies largely come from observational studies. 3. Partial benefit with substantial residual burden. GECSEN suggests considering a second preventive. Depending on migraine subtype and comorbidities, the discussion may include conventional oral agents, onabotulinumtoxinA, CGRP monoclonal antibodies or gepants. The consensus does not establish that every combination has equivalent evidence or suitability.
5. Interpret the two 12-month recommendations in context
| Source | Treatment and timing |
|---|---|
| Taiwan Headache Society | CGRP-targeted therapy may continue for up to 12 months in episodic or chronic migraine. The update emphasises avoiding premature interruption. |
| Spanish GECSEN consensus | Generally maintain preventive treatment for at least 12 months after achieving optimal control, then consider withdrawal jointly with the patient. |
Document which recommendation applies and when optimal control was first reached. The Spanish maintenance interval starts from control rather than treatment initiation.
6. Plan follow-up after withdrawal
Agree with the patient on how to track headache frequency and quality of life after stopping. GECSEN advocates close follow-up and reintroduction if migraine recurs at more than four attacks per month. Use this threshold with the patient’s functional impact and prior response when discussing recurrence. The panel identifies uncertainty around sustained benefit after cessation and calls for randomised studies to establish whether CGRP therapies modify the course of the disease.
